LLY - Eli Lilly and Company
NEXT EARNINGS:
Apr 30, 2026
EPS Est: $7.22
|
Rev Est: $17.4B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$1214.28
DETAILS
HIGH:
$1350.00
LOW:
$830.00
MEDIAN:
$1255.00
CONSENSUS:
$1214.28
UPSIDE:
16.52%
Market Cap:
983.12B
Volume:
2,165,740
Avg Volume:
3,265,500
52 Week Range:
623.78-1133.95
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.39
Last Dividend:
$6.23
Exchange:
NYSE
Country:
US
Employees:
47,000
IPO Date:
1972-06-01
EPS (TTM):
23.00
P/E Ratio:
46.76
Revenue (TTM):
65.18B
Total Assets:
112.48B
Total Debt:
42.50B
Cash & Equiv:
7.16B
Rev Growth (5Y):
21.6%
EPS Growth (5Y):
28.9%
FCF Growth (5Y):
15.0%
ROCE:
34.1%
Debt/Equity:
1.60
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $7.54 | $6.91 | +9.1% | $19.3B | $17.9B | +7.5% |
| 2025-10-30 | $7.02 | $5.69 | +23.4% | $17.6B | $16.1B | +9.6% |
| 2025-08-07 | $6.31 | $5.60 | +12.7% | $15.6B | $14.7B | +5.8% |
| 2025-05-01 | $3.34 | $3.26 | +2.5% | $12.7B | $12.7B | +0.5% |
| 2025-02-06 | $5.32 | $5.03 | +5.8% | $13.5B | — | — |
| 2024-10-30 | $1.18 | $1.47 | -19.7% | $11.4B | $12.1B | -5.4% |
| 2024-08-08 | $3.92 | $2.60 | +50.8% | $11.3B | $10.0B | +13.2% |
| 2024-04-30 | $2.58 | $2.46 | +4.9% | $8.8B | $8.9B | -1.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B | 22.32B | 21.49B | 19.97B | 21.22B | 19.96B | 19.62B |
| Net Income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 8.32B | 3.23B | (204.10M) | 2.74B | 2.41B | 2.39B |
| EPS | 23.00 | 11.76 | 5.83 | 6.57 | 5.85 | 6.47 | 8.69 | 3.14 | -0.19 | 2.49 | 2.18 | 2.15 |
| Total Assets | 112.48B | 78.71B | 64.01B | 49.49B | 48.81B | 46.63B | 39.29B | 43.91B | 44.98B | 38.81B | 35.57B | 36.31B |
| Total Debt | 42.50B | 33.64B | 25.23B | 16.24B | 16.88B | 16.60B | 15.80B | 10.30B | 13.65B | 10.31B | 7.98B | 8.06B |
| Cash & Equivalents | 7.16B | 3.27B | 2.82B | 2.07B | 3.82B | 3.66B | 2.34B | 7.32B | 6.54B | 4.58B | 3.67B | 3.87B |
| Operating Cash Flow | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B | 6.50B | 4.84B | 5.52B | 5.62B | 4.85B | 2.96B | 4.46B |
| Free Cash Flow | 8.97B | 414.30M | (3.15B) | 4.60B | 5.39B | 4.47B | 3.48B | 2.51B | 3.45B | 3.76B | 1.34B | 2.89B |
| FCF per Share | 9.99 | 0.46 | -3.50 | 4.84 | 5.65 | 4.67 | 3.64 | 2.44 | 3.28 | 3.41 | 1.21 | 2.60 |
| Book Value | 26.54B | 14.19B | 10.77B | 10.65B | 8.98B | 5.64B | 2.61B | 9.83B | 11.59B | 14.01B | 14.57B | 15.37B |
| Cash & ST Investments | 7.27B | 3.42B | 2.93B | 2.21B | 3.91B | 3.68B | 2.44B | 7.41B | 8.03B | 6.04B | 4.45B | 4.83B |
| ROC Equity | 0.78 | 0.75 | 0.49 | 0.59 | 0.62 | 1.10 | 3.19 | 0.33 | -0.02 | 0.20 | 0.17 | 0.16 |